Abstract Library

#769 Surgicial Management of Gastroenteropancreatic Neuroendocrine Tumors: Early and Long-Term Results

Introduction: Surgery could improve survival of gastroenteropancreatic neuroendocrine tumors (GEP NET). Nevertheless, data on survival prognostic factors come from studies focusing on heterogeneous population including both resected and non-resected patients.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Russolillo N, Ferrero A, Vigano' L, Bertuzzo F, Razzore P,

Keywords: GEP-NET, surgery,

#766 Aggressive Surgery for Pancreatic Neuroendocrine Tumors

Introduction: The role of surgery for advanced pancreatic neuroendocrine tumor (pNET) requiring extended resections is not well-defined.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Russolillo N, Vigano' L, Ferrero A, Razzore P, Bertuzzo F,

Keywords: pNET, aggressive surgery,

#506 Paraneoplastic Neurological Syndrome in a Patient with a Pancreatic Well-Differentiated Endocrine Tumor

Introduction: Few studies report the association of neurological syndromes with a carcinoid, the majority being small-cell lung cancer.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Brizzi M, Ferrero A, Ottone A, Bellini E, Bitossi R,

Keywords: paraneoplastic syndrome,

#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma

Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels<30 mg/dl, insulin 150 microUI/ml, and C-peptide at upper normal limits. Endocrinologist prescribed prednisone, diazoxide and recombinant glucagon for hypoglicemic crisis, with little benefit. In March 2010, the patient was given radio-labelled Lu-177-OCTREOTATE treatment. After three cycles, hypoglicemic symptoms were still uncontrolled. CT scan showed stable disease.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ferrero A, Bellini E, Brizzi M, Pia A, Ottone A,

Keywords: malignant insulinoma, everolimus, resistant hypoglycemia,

#426 An Esophageal Gastrointestinal Stromal Tumor (GIST) in a Patient with MEN-1 Related Pancreatic Gastrinoma

Introduction: Both multiple endocrine neoplasia type 1 (MEN1)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs) are rare neoplasms, and their association has been rarely reported.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Rossi R, Massironi S, Ferrero S, Spampatti M, Conte D,

Keywords: Gastrointestinal Stromal Tumors (GISTs), Multiple Endocrine Neoplasia 1 (MEN-1) syndrome, gastrinoma,